Kishore Turaga

Employment

• Biological E (India) Associate Vice President
  1996 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants
  Contemporary Clinical Trials Communications 2023 DOI: 10.1016/j.conctc.2023.101232
  +Save
• A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM 197 conjugate typhoid vaccine (TyphiBEV TM ) in healthy infants, children, and …
  Human Vaccines & Immunotherapeutics 2022 DOI: 10.1080/21645515.2022.2043103
  +Save
• Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study
  2022 DOI: 10.1101/2022.04.20.22274076
  +Save
• Immunogenic superiority and safety of Biological E CORBEVAX vaccine compared to COVISHIELD (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial
  2022 DOI: 10.1101/2022.03.20.22271891
  +Save
• Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies
  2022 DOI: 10.1101/2022.03.08.22271822
  +Save
• Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies
  2022 DOI: 10.2139/ssrn.4055319
  +Save